Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?Hye Lim Lee, So‐Young Huh, Joong‐Yang Cho et al.|Multiple Sclerosis Journal|2019Cited by 12
A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravisSuk-Won Ahn, In Soo Joo, Byung‐Jo Kim et al.|Journal of the Neurological Sciences|2017Cited by 11
Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South KoreaSu‐Hyun Kim, Ho Jin Kim, Ju‐Hong Min et al.|Journal of Clinical Neurology|2025Cited by 11
Multiple Sclerosis in Korea: A Hospital-Based, Multicenter, Epidemiological StudySu‐Hyun Kim, Ho Jin Kim, Eun‐Jae Lee et al.|Journal of Multiple Sclerosis and Neuroimmunology|2023Cited by 6
Serum Peptide Immunoglobulin G Autoantibody Response in Patients with Different Central Nervous System Inflammatory Demyelinating DisordersHye Lim Lee, Byoung Joon Kim, Jin‐Woo Park et al.|Diagnostics|2021Cited by 5